COVID-19 Associated With Psoriasis

Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis

A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Study Overview

• Status: Recruiting
• Conditions: COVID-19; Psoriasis Patients

Detailed Description

Based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

• Study Type: Observational
• Enrollment (Estimated): 2500

Contacts and Locations

• Study Contact: Name: GANG WANG, M.D.; Phone Number: 13571991903; Email: xjwgang@fmmu.edu.cn
• Study Contact Backup: Name: CHEN YU; Phone Number: 13571991903

Study Locations

• China
  • Chongqing
    • Chongqing, Chongqing, China, 400016
      • Completed
      • The First Affiliated Hospital of Chongqing Medical University
  • Gansu
    • Lanzhou, Gansu, China, 730000
      • Completed
      • The First Hospital of Lanzhou University
  • Guangdong
    • Guangzhou, Guangdong, China, 510091
      • Completed
      • Dermatology Hospital of Southern Medical University
  • Jilin
    • Changchun, Jilin, China, 130041
      • Completed
      • The Second Hospital of Jilin University
  • Liaoning
    • Dalian, Liaoning, China, 116021
      • Completed
      • DaLian Dermatosis Hospital
  • Qinghai
    • Xining, Qinghai, China, 810000
      • Completed
      • Xining First People's Hospital
  • Shaanxi
    • Xi'an, Shaanxi, China, 710032
      • Recruiting
      • Xijing Hospital, The Fourth Military Medical University
      • Contact: Chen Yu
  • Shanghai
    • Shanghai, Shanghai, China, 200443
      • Completed
      • Shanghai Skin Disease Hospital, Tongji University School of Medicine
  • Shenzhen
    • Shenzhen, Shenzhen, China, 518053
      • Completed
      • The University of Hong Kong-Shenzhen Hospital
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Completed
      • West China Hospital, Sichuan University
  • Tianjin
    • Tianjin, Tianjin, China, 300021
      • Completed
      • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
  • Xinjiang
    • Ürümqi, Xinjiang, China, 830001
      • Completed
      • People's Hospital of Xinjiang Uygur Autonomous Region，Xinjiang Key Laboratory of Dermatology Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Psoriasis patients registered in the database from January 2018 to November 2022

Description

Inclusion criteria ----

1. No age limit, both male and female are accepted;
2. Psoriasis patients registered in the database;
3. Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

Exclusion criteria ----

Patients are thought having conditions which are not appropriated for attending this clinical trial.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection	The impact of SARS-CoV-2 infection on psoriasis in patients receiving different baseline therapies of psoriasis.	March 15,2023 to May 30,2023

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection	Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection	March 15,2023 to May 30,2023

Collaborators and Investigators

• Sponsor: Gang Wang, MD
• Investigators: Principal Investigator: GANG WANG, M.D., Xijing Hospital, The Fourth Military Medical University

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2023
• Primary Completion (Actual): May 30, 2023
• Study Completion (Estimated): July 30, 2023

Study Registration Dates

• First Submitted: July 25, 2023
• First Submitted That Met QC Criteria: July 25, 2023
• First Posted (Actual): July 27, 2023

Study Record Updates

• Last Update Posted (Actual): August 1, 2023
• Last Update Submitted That Met QC Criteria: July 26, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: covid-19; psoriasis
• Additional Relevant MeSH Terms: Skin Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Skin Diseases, Papulosquamous; COVID-19; Psoriasis
• Other Study ID Numbers: XJPF202303-PSO&COVID-19

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No